{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T20:43:30Z","timestamp":1775940210027,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T00:00:00Z","timestamp":1144281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec>\n                    <jats:label\/>\n                    <jats:p>A group of authors from the USA evaluated the efficacy and tolerability of tolterodine extended\u2010release on objective and subjective endpoints in men with an overactive bladder. They found that it significantly reduced incontinent episodes and improved patient perception of treatment benefit in men with an overactive bladder<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the efficacy and tolerability of tolterodine extended\u2010release (ER) on objective and subjective endpoints in men with overactive bladder (OAB) and urgency urinary incontinence (UI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      This was a\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis of data collected from men with OAB enrolled in a 12\u2010week, double\u2010blind, placebo\u2010controlled trial of tolterodine ER (4\u2003mg once daily; tolterodine ER registration trial) and included men with urinary frequency (\u22658 micturitions\/24\u2003h) and urgency UI (\u22655 episodes\/week). UI episodes were assessed using 7\u2010day bladder diaries. Patient perception of treatment benefit was evaluated after 12\u2003weeks. Adverse events (AEs) were recorded throughout the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      In all, 163 men with OAB (placebo, 86; tolterodine ER, 77; mean age 65\u2003years) were evaluated. Baseline demographics and clinical characteristics were similar for the two treatment groups. Compared with placebo, tolterodine ER significantly reduced weekly UI episodes (median % change, \u221271% vs \u2212\u200a40%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003&lt;\u20030.05; mean numeric change, \u2212\u200a11.9 vs \u22125.9,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.02). Men receiving tolterodine ER had fewer micturitions\/24\u2003h, but this was not a significant difference from placebo (median % change, \u221212% vs \u2212\u200a4%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.22). Significantly more men treated with tolterodine\u2010ER (63%) than placebo\u2010treated men (46%) reported a benefit of treatment after 12\u2003weeks (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.04). The most commonly reported AEs associated with tolterodine\u2010ER vs placebo were dry mouth (16% vs 7%), constipation (4% vs 9%), dyspepsia (4% vs 1%), dizziness (5% vs 1%), and somnolence (3% vs 1%). One of the men receiving tolterodine ER had symptoms suggestive of urinary retention that led to his withdrawal from the study. None of the men had acute urinary retention requiring catheterization.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>In men with OAB and urgency UI, tolterodine ER was well tolerated and significantly reduced episodes of urgency UI, and improved patient perception of treatment benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06068.x","type":"journal-article","created":{"date-parts":[[2006,4,6]],"date-time":"2006-04-06T12:25:13Z","timestamp":1144326313000},"page":"1003-1006","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Efficacy and tolerability of tolterodine extended\u2010release in men with overactive bladder and urgency urinary incontinence"],"prefix":"10.1111","volume":"97","author":[{"given":"CLAUS G.","family":"ROEHRBORN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PAUL","family":"ABRAMS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ERIC S.","family":"ROVNER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"STEVEN A.","family":"KAPLAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SENDER","family":"HERSCHORN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHONGHONG","family":"GUAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74008.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005392-200101000-00072"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1987.tb05033.x"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000139986.08972.e3"},{"key":"e_1_2_7_9_2","first-page":"F885","article-title":"Changes in electrical properties of guinea pig smooth muscle membrane by experimental bladder outflow obstruction","volume":"262","author":"Seki N","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)65982-4"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.05158.x"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65075-4"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_7_14_2","unstructured":"PleilA CoyneKS ReesePR JumadilovaZ KelleherC.Confirming the validity of patient global impressions as outcome measures in overactive bladder. Presented at: 20th Congress of the European Association of Urology;2005 March 1619; Istanbul Turkey"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2.10.1685"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)62382-3"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201987"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007094"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00540-7","article-title":"Antimuscarinics and the overactive detrusor \u2013 which is the main mechanism of action?","volume":"43","author":"Andersson KE","year":"2003","journal-title":"Eur Urol"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04526.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00986-4"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2003.10.037"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06068.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06068.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:58:19Z","timestamp":1761739099000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06068.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,6]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06068.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06068.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,6]]},"assertion":[{"value":"2006-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}